By Fineline Cube China’s National Health Commission (NHC), together with the National Administration of Traditional Chinese Medicine and the National Disease Control and Prevention Administration, jointly issued the Notice on Ensuring Priority Allocation and Use of Essential Medicines, laying out binding implementation measures following the release of the 2026 edition of the National Essential Medicines List.
Policy Milestone
| Item | Detail |
|---|---|
| Issuing Bodies | NHC; National Administration of Traditional Chinese Medicine; National Disease Control and Prevention Administration |
| Policy | Notice on Ensuring Priority Allocation and Use of Essential Medicines |
| Trigger | Release of the 2026 edition of the National Essential Medicines List |
| Scope | All public medical and health institutions nationwide |
| Catalog Update Deadline | Within two months of the new edition taking effect |
| Annual Reporting Deadline | 10 December each year |
Key Requirements for Public Institutions
- Catalog Updates: All public medical and health institutions must complete updates to their drug supply catalogs within two months of the new edition taking effect, giving priority to essential medicines
- Unified Catalog Management: Closely integrated medical alliances must strengthen unified drug catalog management with a dynamic adjustment cycle of no more than one year, and promptly expand the range of essential medicine varieties available at primary‑level institutions
- Provincial Targets: Provincial health administrations are directed to set proportions of essential medicines by variety count, usage volume, expenditure, and prescription share — with annual increases expected
- Prescription Priority: Public institutions must mark essential medicines in their information systems to flag them for priority use; physicians are required to preferentially prescribe national essential medicines when clinical efficacy is comparable
Monitoring, Training & Enforcement Mechanisms
| Mechanism | Requirement |
|---|---|
| Use Monitoring | Strengthened drug‑use monitoring and comprehensive clinical evaluation to promote precise, rational use |
| Training Coverage | Full coverage of essential‑medicine training for physicians and pharmacists in public institutions |
| Performance Linkage | Allocation and use incorporated into healthcare reform and performance assessments |
| Funding Tie‑In | Evaluation results linked to the disbursement of subsidy funds |
| Reporting | All provinces must submit assessment reports to the NHC by 10 December each year |
Market Impact & Outlook
- Demand Shift for Listed Products: Mandatory proportional targets and priority prescription rules are set to steer meaningful volume toward drugs on the National Essential Medicines List, benefiting manufacturers with listed varieties while pressuring non‑listed alternatives
- Primary‑Care Expansion: Requiring primary‑level institutions to broaden essential‑medicine availability deepens market penetration in China’s grassroots healthcare system, a growth frontier for volume‑oriented generic and TCM producers
- Enforcement Teeth: Linking evaluation results to subsidy disbursement — combined with hard annual reporting deadlines — gives the policy stronger enforcement mechanics than prior exhortatory guidance
- Industry Implications: Pharmaceutical companies should reassess portfolio positioning ahead of the list’s implementation, as procurement priorities, formulary access, and prescribing behavior across public hospitals realign around the 2026 list
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the implementation and market impact of China’s essential medicines policy. Actual results may differ due to risks including provincial execution variability, list composition changes, and procurement and pricing dynamics.-Fineline Info & Tech